Dr. Kulbir Rangi is a Philadelphia, Pennsylvania based physiatrist who is specialized in Pain Management (PM&R). Active license number of Dr. Kulbir Rangi as Pain Management (PM&R) is OS020322 in Pennsylvania.
Dr. Kulbir Rangi provides a high level of care, either as a primary physician or consultant, for patients experiencing problems with acute, chronic or cancer pain in both hospital and ambulatory settings. Patient care needs may also be coordinated with other specialists.
Complete Profile:
Dr. Kulbir Rangi speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Pain Management (PM&R)
Credentials:
DO
Gender:
Male
Practice Address:
1420 Walnut St Ste 406, Philadelphia, Pennsylvania, 19102-4003
Phone:
856-482-7246
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1588309876
NPI Enumeration Date:
01 May, 2022
NPI Last Update On:
01 May, 2022
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Kulbir Rangi are as mentioned below.
License Number
Specialization
State
Status
OS020322
Pain Management
Pennsylvania
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1420 Walnut St Ste 406, Philadelphia, Pennsylvania
Zip:
19102-4003
Phone Number:
856-482-7246
Fax Number:
--
Patients can reach Dr. Kulbir Rangi at 1420 Walnut St Ste 406, Philadelphia, Pennsylvania or can call to book an appointment on 856-482-7246. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 July, 2025.